PE58999A1 - Tabletas de oxacarbazepina recubiertas de pelicula - Google Patents

Tabletas de oxacarbazepina recubiertas de pelicula

Info

Publication number
PE58999A1
PE58999A1 PE1998000100A PE00010098A PE58999A1 PE 58999 A1 PE58999 A1 PE 58999A1 PE 1998000100 A PE1998000100 A PE 1998000100A PE 00010098 A PE00010098 A PE 00010098A PE 58999 A1 PE58999 A1 PE 58999A1
Authority
PE
Peru
Prior art keywords
oxacarbazepine
tablets
refers
film coated
production
Prior art date
Application number
PE1998000100A
Other languages
English (en)
Inventor
Burkhard Schlutermann
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4184588&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE58999(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE58999A1 publication Critical patent/PE58999A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
    • C07D223/22—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A UNA FORMULACION QUE COMPRENDE OXACARBAZEPINA FINAMENTE MOLIDA QUE TIENE UN TAMANO DE PARTICULA DE 2 A 12 MICRAS, Y CON UN RESIDUO MAXIMO SOBRE UN TAMIZ DE 40 MICRAS DE HASTA EL 5%. TAMBIEN SE REFIERE A UNA TABLETA RECUBIERTA POR UNA PELICULA QUE COMPRENDE a)UN NUCLEO DE TABLETA QUE CONTIENE OXACARBAZEPINA FINAMENTE MOLIDA Y OTROS EXCIPIENTES ADECUADOS PARA LA PRODUCCION DE GRANULOS. b)UN RECUBRIMIENTO EXTERNO HIDROFILICO PERMEABLE. TAMBIEN SE REFIERE A UN PROCESO PARA SU PRODUCCION
PE1998000100A 1997-02-14 1998-02-11 Tabletas de oxacarbazepina recubiertas de pelicula PE58999A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH33197 1997-02-14

Publications (1)

Publication Number Publication Date
PE58999A1 true PE58999A1 (es) 1999-06-25

Family

ID=4184588

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998000100A PE58999A1 (es) 1997-02-14 1998-02-11 Tabletas de oxacarbazepina recubiertas de pelicula

Country Status (32)

Country Link
US (2) US20070036863A1 (es)
EP (1) EP0966287B1 (es)
JP (3) JP2000511935A (es)
KR (3) KR19980071337A (es)
CN (2) CN1626093A (es)
AR (1) AR011142A1 (es)
AT (1) ATE239481T1 (es)
AU (1) AU738030B2 (es)
BR (1) BR9807368A (es)
CA (1) CA2277791C (es)
CO (1) CO4920215A1 (es)
CY (1) CY2480B1 (es)
CZ (1) CZ298840B6 (es)
DE (1) DE69814367T2 (es)
DK (1) DK0966287T3 (es)
ES (1) ES2199422T3 (es)
HK (1) HK1024423A1 (es)
HU (1) HU227807B1 (es)
ID (1) ID22348A (es)
MY (1) MY117582A (es)
NO (1) NO327486B1 (es)
NZ (1) NZ336946A (es)
PE (1) PE58999A1 (es)
PL (1) PL193332B1 (es)
PT (1) PT966287E (es)
RU (1) RU2201218C2 (es)
SK (1) SK284503B6 (es)
TR (1) TR199901804T2 (es)
TW (1) TW529957B (es)
UY (1) UY24888A1 (es)
WO (1) WO1998035681A1 (es)
ZA (1) ZA981205B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4920215A1 (es) * 1997-02-14 2000-05-29 Novartis Ag Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
GB9925962D0 (en) * 1999-11-02 1999-12-29 Novartis Ag Organic compounds
US6368628B1 (en) * 2000-05-26 2002-04-09 Pharma Pass Llc Sustained release pharmaceutical composition free of food effect
BR0215193A (pt) 2001-12-21 2004-11-16 Pfizer Prod Inc Formulações de azitromicina diretamente compressìveis
GB0221956D0 (en) * 2002-09-20 2002-10-30 Novartis Ag Organic compounds
KR20060118426A (ko) 2003-09-03 2006-11-23 노파르티스 아게 당뇨병성 신경병증성 통증 치료 및 수면 개선을 위한옥스카르바제핀의 용도
PE20051156A1 (es) * 2004-03-22 2006-02-13 Novartis Ag Formulaciones de matriz orales que comprenden licarbazepina
AR048672A1 (es) * 2004-03-22 2006-05-17 Novartis Ag Tabletas de desintegracion que comprenden licarbazepina
US8367105B2 (en) 2004-11-10 2013-02-05 Teva Pharmaceutical Industries, Ltd. Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
DK1928427T3 (da) 2005-09-23 2010-03-08 Hoffmann La Roche Hidtil ukendt dosisformulering
HUE032640T2 (en) 2005-11-08 2017-10-30 Vertex Pharma Heterocyclic modulator of ATP-binding cassette transcripts
WO2007053904A1 (en) 2005-11-10 2007-05-18 Alphapharm Pty Ltd Process to control particle size
AU2006313009B2 (en) * 2005-11-10 2013-10-24 Alphapharm Pty Ltd Process to control particle size
WO2007089247A1 (en) * 2006-01-31 2007-08-09 Teva Pharmaceutical Industries Ltd. Oxcarbazepine pharmaceutical formulation and its method of preparation, wherein oxcarbazepine has a broad and multi-modal particle size distribution
EP2029118A2 (en) * 2006-01-31 2009-03-04 Teva Pharmaceutical Industries, Inc. Oxcarbazepine pharmaceutical formulation and its method of preparation, wherein oxcarbazepine has a broad and multi-modal particle size distribution
AU2007242062A1 (en) * 2006-04-21 2007-11-01 Alphapharm Pty Ltd Pharmaceutical compositions of oxcarbazepine with a median particle size of 15 to 30 microns
EP2359830B1 (en) * 2006-04-26 2012-09-19 Supernus Pharmaceuticals, Inc. Controlled released preparations of oxcarbazepine having sigmoidal release profile
EP2018157A2 (en) 2006-04-26 2009-01-28 Astron Research Limited Controlled release formulation comprising anti-epileptic drugs
US20080138403A1 (en) * 2006-12-08 2008-06-12 Sun Pharmaceutical Industries Ltd. Pharmaceutical dosage forms of oxcarbazepine
EP2114404A4 (en) 2006-12-21 2010-03-03 Alphapharm Pty Ltd COMPOUND AND PHARMACEUTICAL COMPOSITION
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
EP1970056A1 (en) * 2007-03-15 2008-09-17 Polichem S.A. Time-specific delayed/pulsatile release dosage forms
EP2146699A2 (en) * 2007-05-23 2010-01-27 Ratiopharm GmbH Pharmaceutical compositions comprising oxcarbazepine
US8372431B2 (en) 2007-10-26 2013-02-12 Bial-Portela & C.A., S.A. Pharmaceutical composition comprising licarbazepine acetate
KR20100101130A (ko) 2007-12-07 2010-09-16 버텍스 파마슈티칼스 인코포레이티드 3-(6-(1-(2,2-디플루오로벤조[ｄ][1,3]디옥솔-5-일)사이클로프로판카복스아미도)-3-메틸피리딘-2-일)벤조산의 고체 형태
LT3150198T (lt) 2010-04-07 2021-12-10 Vertex Pharmaceuticals Incorporated 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiridin-2-il)benzoinės rūgšties farmacinė kompozicija ir jos įvedimas
PT3068392T (pt) 2013-11-12 2021-05-14 Vertex Pharma Processo de preparação de composições farmacêuticas para o tratamento de doenças mediadas por condutância transmembrana da fibrose quística (cftr)
CN103735527B (zh) * 2013-12-24 2014-09-10 武汉人福药业有限责任公司 一种奥卡西平片剂及其制备方法
WO2018208242A1 (en) 2017-05-10 2018-11-15 İlko Ilaç Sanayi Ve Ticaret Anonim Şirketi Formulation of deferasirox tablet for oral suspension composition with better processability

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI75561C (fi) * 1979-10-30 1988-07-11 Ciba Geigy Ag Foerfarande foer framstaellning av 5- karbamoyl-10-oxo-10,11-dihydro-5h-dibens/b,f/azepin och daertill noedvaendiga mellanprodukter.
CH649080A5 (de) * 1981-04-16 1985-04-30 Ciba Geigy Ag 5h-dibenz(b,f)azepin-5-carboxamide als mittel zur prophylaxe und behandlung von zerebraler leistungsinsuffizienz.
US4609675A (en) * 1984-08-17 1986-09-02 The Upjohn Company Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing
JPS6257467A (ja) * 1985-09-06 1987-03-13 Asahi Glass Co Ltd コ−テイング剤組成物
GB8524001D0 (en) * 1985-09-30 1985-11-06 Glaxo Group Ltd Pharmaceutical composition
CH668187A5 (de) * 1986-08-07 1988-12-15 Ciba Geigy Ag Therapeutisches system mit systemischer wirkung.
DD295760A5 (de) * 1989-01-31 1991-11-14 Martin-Luther-Universitaet Halle Wittenberg,De Arzneistoffreigabesystem mit kotrollierter wirkstoffreisetzung
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5231089A (en) * 1991-12-02 1993-07-27 University Of Florida Method of improving oral bioavailability of carbamazepine
FR2699077B1 (fr) * 1992-12-16 1995-01-13 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes.
FR2702148B1 (fr) * 1993-03-05 1995-04-07 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement du neuro-sida.
US5472714A (en) * 1993-09-08 1995-12-05 Ciba-Geigy Corporation Double-layered oxcarbazepine tablets
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
US5478654A (en) * 1994-05-06 1995-12-26 Gencorp Inc. Solventless carboxylated butadiene-vinylidene chloride adhesives for bonding rubber to metal
US5980942A (en) * 1997-01-23 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Zero-order sustained release matrix tablet formulations of carbamazepine
US6296873B1 (en) * 1997-01-23 2001-10-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Zero-order sustained release delivery system for carbamazephine derivatives
CO4920215A1 (es) * 1997-02-14 2000-05-29 Novartis Ag Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones

Also Published As

Publication number Publication date
KR20090037873A (ko) 2009-04-16
UY24888A1 (es) 2000-12-29
AR011142A1 (es) 2000-08-02
CN1170542C (zh) 2004-10-13
DK0966287T3 (da) 2003-08-25
RU2201218C2 (ru) 2003-03-27
PL193332B1 (pl) 2007-02-28
KR19980071337A (ko) 1998-10-26
NZ336946A (en) 2001-02-23
HU227807B1 (en) 2012-03-28
CN1626093A (zh) 2005-06-15
DE69814367D1 (de) 2003-06-12
HK1024423A1 (en) 2000-10-13
ID22348A (id) 1999-09-30
SK284503B6 (sk) 2005-05-05
ZA981205B (en) 1998-08-14
EP0966287B1 (en) 2003-05-07
US20070036863A1 (en) 2007-02-15
JP2000511935A (ja) 2000-09-12
CN1247471A (zh) 2000-03-15
ES2199422T3 (es) 2004-02-16
AU6622298A (en) 1998-09-08
NO993919L (no) 1999-08-13
JP2010132694A (ja) 2010-06-17
SK109899A3 (en) 2000-03-13
TW529957B (en) 2003-05-01
AU738030B2 (en) 2001-09-06
PL334959A1 (en) 2000-03-27
DE69814367T2 (de) 2004-02-26
BR9807368A (pt) 2000-03-14
CZ287999A3 (cs) 1999-11-17
ATE239481T1 (de) 2003-05-15
CA2277791A1 (en) 1998-08-20
CY2480B1 (en) 2005-06-03
WO1998035681A1 (en) 1998-08-20
HUP0000886A2 (hu) 2000-09-28
CZ298840B6 (cs) 2008-02-20
JP2006077029A (ja) 2006-03-23
EP0966287A1 (en) 1999-12-29
CA2277791C (en) 2008-11-18
US20080014269A1 (en) 2008-01-17
HUP0000886A3 (en) 2002-10-28
CO4920215A1 (es) 2000-05-29
KR20120079826A (ko) 2012-07-13
PT966287E (pt) 2003-09-30
TR199901804T2 (xx) 1999-09-21
NO327486B1 (no) 2009-07-13
NO993919D0 (no) 1999-08-13
MY117582A (en) 2004-07-31

Similar Documents

Publication Publication Date Title
PE58999A1 (es) Tabletas de oxacarbazepina recubiertas de pelicula
BR9204887A (pt) Processo para formar sobre um substrato solido uma pelicula de propriedade similares as do diamante,os corpos solidos assim revestidos e a pelicula revestida assim obtida
PE20030638A1 (es) Formulacion granular de montelukast sodico
BR0109198A (pt) Emplastro com filtro ultravioleta
ES2097536T3 (es) Perlas dotadas de un nucleo con un antifungico y un polimero.
DE69009540T2 (de) Arzneimittel enthaltendes Heftpflaster.
AR002275A1 (es) Forma de dosificacion farmaceutica oral, procedimiento para la manufactura de una forma de dosificacion fija, y uso de dicha forma de dosificacionfarmaceutica oral.
DK1077680T3 (da) Fremgangsmåde til fremstilling af en med bånd forsynet aktivt-stof-doseringsform til prolongeret release
ES2157297T3 (es) Granulos entericos de duloxetina.
HUP0201788A2 (en) Multilayered film containing an active substance and made of cross-linked hydrophilic polymers
DK1077727T3 (da) Sammensætning til adhæsiv mikrosfærelægemiddelafgivelse
AR018704A1 (es) Parche con efecto de campo magnetico
ATE250233T1 (de) Vorrichtung mit einer miniaturisierten gammakamera mit sehr hoher räumlicher auflösung
ES2120430T3 (es) Pastillas o comprimidos que contienen material genetico y portador inerte para los mismos y metodo para su preparacion.
AR025052A1 (es) Derivados de 2-dialquilaminoalquilbifenilo sustituidos, procedimiento para su preparacion, medicamentos que contienen estos compuestos y el uso de estoscompuestos para la preparacion de medicamentos.
BRPI9913444B8 (pt) suporte em forma de película para uma substância ativa.
PT994887E (pt) Glicosidos modificados composicoes que compreendem os mesmos e metodos para a sua utilizacao
DE69512638D1 (de) Schnell auflösende orale darreichungsform
IT8224724A0 (it) Procedimento per la metallizzazione fortemente adesiva dei materiali ceramici.
FI832025L (fi) Faergade graverade foeremaol
ES2055291T5 (es) Material de gel acrilico y preparacion de gel acrilico.
RS50246B (sr) Tableta za sisanje, koja sadrži ambroksol
ITTO990959A0 (it) Procedimento per la produzione di materiali polimerici espansi e estru sore per la sua attuazione.
AR006565A1 (es) Suspensiones acuosas de beta-ciflutrina
DE59706576D1 (de) Orale zubereitung, enthaltend in einer in wässrigem medium quellbaren matrix wenigstens einen pharmazeutischen wirkstoff

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed